Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
- Previous Close
1.9700 - Open
2.0000 - Bid 1.9900 x --
- Ask 2.0000 x --
- Day's Range
1.9600 - 2.0100 - 52 Week Range
1.6600 - 2.4400 - Volume
400,900 - Avg. Volume
144,509 - Market Cap (intraday)
3.106B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
11.11 - EPS (TTM)
0.1800 - Earnings Date --
- Forward Dividend & Yield 0.16 (7.91%)
- Ex-Dividend Date May 26, 2023
- 1y Target Est
--
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was founded in 1981 and is based in Tianjin, the People's Republic of China.
www.jydrt.com.cn4,619
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: T14.SI
Performance Overview: T14.SI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: T14.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: T14.SI
Valuation Measures
Market Cap
3.10B
Enterprise Value
2.86B
Trailing P/E
11.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
1.69
Enterprise Value/Revenue
0.35
Enterprise Value/EBITDA
2.26
Financial Highlights
Profitability and Income Statement
Profit Margin
12.00%
Return on Assets (ttm)
4.90%
Return on Equity (ttm)
14.68%
Revenue (ttm)
8.22B
Net Income Avi to Common (ttm)
986.71M
Diluted EPS (ttm)
0.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.19B
Total Debt/Equity (mrq)
5.10%
Levered Free Cash Flow (ttm)
365.73M
Research Analysis: T14.SI
Company Insights: T14.SI
T14.SI does not have Company Insights